Ignite Creation Date:
2025-12-24 @ 10:22 PM
Ignite Modification Date:
2026-01-05 @ 4:38 AM
Study NCT ID:
NCT03025035
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-02
First Post:
2017-01-17
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
Sponsor:
Yuan Yuan
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-09-10
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-08-08
Completion Date Type:
ESTIMATED
First Submit Date:
2017-01-17
First Submit QC Date:
None
Study First Post Date:
2017-01-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2025-04-29
Results First Submit QC Date:
None
Results First Post Date:
2025-05-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-14
Last Update Post Date:
2025-12-02
Last Update Post Date Type:
ESTIMATED